Bilateral Infant Stimulation Study
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Apr 5, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Bilateral Infant Stimulation Study is exploring how parents of babies in the neonatal intensive care unit (NICU) experience stress and anxiety. The researchers want to see if a new technique called bilateral alternating stimulation can help reduce this stress and improve the emotional connection between parents and their babies. Parents who participate will fill out surveys about their stress levels and feelings of bonding with their child before and after the intervention, which will take place at the baby's bedside. The study will also monitor the vital signs of both the parent and baby to understand how they respond to the intervention.
To be eligible for the study, parents must have a baby in the NICU who is between 34 to 43 weeks of age. The baby should also be within four weeks of their NICU admission. It's important that the parent or legal guardian is willing to take part in the study. However, parents who have had surgery recently, are taking certain medications that affect the brain, or have specific medical conditions may not be able to participate. This study aims to create a supportive environment for families during a challenging time and to understand better how to improve parent-child relationships in the NICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • admitted to the NICU at the time of study
- • greater than 34 weeks gestational age and less than 43 weeks gestational age
- • within 4 weeks of admission to NICU at time of initial contact
- • have parent or legal guardian willing and able to participate in the study
- Exclusion Criteria:
- • those who are less than 3 days postop from surgical procedures
- • current use of psychotropic medications or medications that affect the central nervous system (CNS)
- • CNS anomaly.
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported